NCR3LG1 and acute myeloid leukemia: In order to evaluate the efficacy of CAR engineered T cells in vivo, we ideally sought to test NKp30 CAR redirected T cells in a patient-tailored NSG AML-xenograft model expressing moderate B7H6 levels on the AML cells.